Draft:Peter Fedichev

• Comment: You cannot use preprints, these are not peer reviewed. I cannot find evidence of a pass of either academic or general notability. Ldm1954 (talk) 13:58, 31 October 2025 (UTC)

---

Peter Fedichev
Born	Peter Olegovich Fedichev
Alma mater	Moscow Institute of Physics and Technology (M.S.); University of Amsterdam (Ph.D.)
Occupation(s)	Physicist, biotechnologist, entrepreneur
Known for	Research on quantitative models of ageing; co-founding Gero.ai

Peter Olegovich Fedichev is a physicist and biotechnologist. He is the co-founder and chief executive officer of Gero.ai, a biotechnology company based in Singapore that applies physics-based and machine-learning methods to ageing and disease research. His academic background is in theoretical physics, and his later work explores quantitative models of biological ageing sometimes described as “Gerophysics.”

Education and early career

Fedichev received an M.Sc. in theoretical physics from the Moscow Institute of Physics and Technology while conducting research at the Kurchatov Institute. In 1994 he joined the University of Amsterdam and the AMOLF institute, completing a Ph.D. cum laude in theoretical physics. He later worked at the University of Innsbruck on condensed-matter and quantum-gas systems.

Research

During the 2000s Fedichev co-founded Quantum Pharmaceuticals, an early company exploring computational drug design. Since 2015 he has led Gero.ai, whose studies use large health datasets and mathematical models to analyse ageing dynamics., In 2021 a collaboration with academic partners reported that human blood-biomarker variability increases with age, suggesting limits to resilience.

Contributions to Gerophysics

Fedichev has written on the use of physical and mathematical approaches to describe biological ageing. He and co-authors have proposed that the progression of ageing can be treated as a problem in non-equilibrium thermodynamics and complex-systems dynamics. This line of work, sometimes referred to as Gerophysics, links physical measures of system stability and entropy with physiological decline observed in longitudinal human data.

Fedichev and collaborators have published models describing how variability in health indicators increases with age and may predict lifespan limits. Subsequent studies extended this framework to distinguish between processes that might be reversible through intervention and those that appear thermodynamically irreversible. A later preprint introduced the concept of an “effective temperature” as a quantitative variable influencing the rate of ageing across mammals.

Nature highlighted these developments in its 2024 “Gerophysics” article collection, co-edited by Fedichev and biologist Brian K. Kennedy, describing the field as an emerging interdisciplinary area linking statistical physics and biogerontology.

Public debates

In 2024 Fedichev took part in a public discussion with biogerontologist Aubrey de Grey at the Foresight Institute in San Francisco titled “How to Defeat Aging.” The debate, organized by the group Open Longevity, examined whether human ageing could be reversed or only slowed. Reports in science and longevity media noted contrasting perspectives between the two speakers and described the event as an example of renewed public debate on strategies for life-extension research.

Gero.ai

Gero.ai was co-founded in 2018 by Fedichev and Maxim Kholin in Singapore. The company develops physics-informed AI models trained on electronic medical records and molecular-level data to predict health trajectories and identify potential therapeutic targets for ageing-related conditions. Gero has reported collaborations with Pfizer on fibrotic-disease research and with Chugai Pharmaceutical, a member of the Roche Group.

Selected publications

• Pyrkov T.V., Avchaciov K., Tarkhov A.E., Denisov K.A., & Fedichev P.O. (2021). “Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit.” Nature Communications, 12 (2765).
• Cortassa S., Fedichev P.O., et al. (2022). “Inhibitors of bacterial H₂S biogenesis targeting antibiotic resistance and tolerance.” Science.
• Tarkhov A.E., Denisov K.A., & Fedichev P.O. (2025). “Aging Clocks, Entropy, and the Challenge of Age Reversal.” Aging Biology, 2:e20240031.
• Fedichev P.O., Gruber J., Denisov K.A. (2024). “Discovery of Thermodynamic Control Variables that Independently Regulate Healthspan and Maximum Lifespan.” Aging Biology.

Reception

Fedichev’s research has been discussed in general-science and technology outlets such as Scientific American, Popular Mechanics, and Longevity.Technology. He has appeared at international meetings including Aging Research and Drug Discovery (ARDD), MedTech World Malta, and the Longevity Investors Conference.

External links

• Official website
• Open Longevity – Debates